Creative Planning’s Oramed Pharmaceuticals ORMP Stock Holding History

Creative Planning’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,000	Closed	-$16K	–	3143
2017 Q2	$16K	Hold	2,000	–	–	﹤0.01%	3328
2017 Q1	$12K	Hold	2,000	–	–	﹤0.01%	3480
2016 Q4	$12K	Hold	2,000	–	–	﹤0.01%	3431
2016 Q3	$15K	Hold	2,000	–	–	﹤0.01%	3245
2016 Q2	$17K	Hold	2,000	–	–	﹤0.01%	2914
2016 Q1	$13K	Hold	2,000	–	–	﹤0.01%	3052
2015 Q4	$17K	Buy	+2,000	New	+$15.2K	﹤0.01%	2952

Other funds holding ORMP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Creative Planning's ORMP Position: Q3 2017 in Review

Creative Planning sold out of Oramed Pharmaceuticals (ORMP) in Q3 2017, closing a stake of 2,000 shares — an estimated $16K sold.

Creative Planning first reported a position in ORMP in Q4 2015 and held it in 7 quarters. The position peaked at $17K in Q2 2016. 22 funds tracked by Wall St. Rank hold ORMP as of Q3 2017.

Creative Planning reported no remaining Oramed Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 2,000 Oramed Pharmaceuticals shares in Q3 2017, an estimated $16K.
Creative Planning first reported a position in Oramed Pharmaceuticals in Q4 2015 and held it in 7 quarters.
Creative Planning's Oramed Pharmaceuticals position peaked at $17K in Q2 2016.
22 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.